The biotech will add a pivotal Phase III cohort to its ongoing Phase I/II trial evaluating ATSN-201 in X-linked retinoschisis ...

The funds will help the firm advance copper-based radioligand therapies and imaging agents in prostate, neuroendocrine, and breast cancers.

The biotech firm eliminated the need for surgical administration in the study by using an infusion catheter system in a cardiac cath lab.

The Whitrod family launched Genetic Cures for Kids in the hopes of finding a treatment for their daughter with hereditary ...

The firm will use the funds to conduct a Phase I/II trial of an adoptive cell therapy designed to activate T regulatory cells against cancer.

Data from a Phase I trial of Avmapki Fakzynja also supports the regimen's tolerability and suggests its potential activity in ...

The firm will use the money to advance its lead FAP-targeting radioligand candidate into clinical development.

The firm is hoping to show that the RNAi drug can treat HoFH by reducing production of ANGPTL3, which regulates lipid and lipoprotein metabolism.

The organizations launched the center with a $20 million CZI grant to build on the success of the first personalized CRISPR base-editing therapy.

Cero will use Invivoscribe's multiparametric flow cytometry assay to detect minimal residual disease in patients and evaluate the therapy's efficacy.

The Phase II trial will compare progression-free survival in lung cancer patients treated according to their molecular subtypes.

The law, slated to take effect in September, requires health plans to cover the treatment given by in-network providers, not ...